Lost password ?
<< Back to Equity Research
UNIMED
UNIMED, A LIMITED POTENTIAL
Jun 06 - The Pharma sector covered by AlphaMena (6 stocks, €728m market cap) has recorded the fifth worst performance since January 2018 (-5.56%). Benefiting from the return of optimism on the Tunisian ...
Executive summary
Conflict of Interest
Pages 34
Language English
Publish on June 6, 2018
€ 500
VAT Exl.
You might be also interested by these reports :
Apr 15 PM
Idea Kicker
JULPHAR, WAITING FOR A SAFETY MARGIN
Mar 19 AM
Gulf Pharmaceutical
A better Q4 lifted our Target Price
Mar 16 PM
Gulf Pharmaceutical
A hit from outside GCC revenues in 2023
Mar 04 PM
Gulf Pharmaceutical
Modest 2023 results despite a better-than-expected Q4
FIND A REPORT
CONCEPT
Each company is researched in depth using a structured robust and transparent process.

AlphaMena provides analyses based upon exhaustive and homogeneous information which allows to compare stocks geographically, sector-wise, and by thematic.

The analyses include actuarial as well as off balance-sheet data.
BloombergStarmineFactsetReutersCapital IQ